CN1313109C - 三子汤新制剂及其制备 - Google Patents
三子汤新制剂及其制备 Download PDFInfo
- Publication number
- CN1313109C CN1313109C CNB2003101001643A CN200310100164A CN1313109C CN 1313109 C CN1313109 C CN 1313109C CN B2003101001643 A CNB2003101001643 A CN B2003101001643A CN 200310100164 A CN200310100164 A CN 200310100164A CN 1313109 C CN1313109 C CN 1313109C
- Authority
- CN
- China
- Prior art keywords
- asthma
- cough
- sub
- preparation
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 31
- 210000000582 semen Anatomy 0.000 title claims description 39
- 241000220261 Sinapis Species 0.000 title description 11
- 239000003814 drug Substances 0.000 claims abstract description 125
- 206010006451 bronchitis Diseases 0.000 claims abstract description 9
- 206010006458 Bronchitis chronic Diseases 0.000 claims abstract description 8
- 208000007451 chronic bronchitis Diseases 0.000 claims abstract description 8
- 208000023819 chronic asthma Diseases 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 120
- 229940079593 drug Drugs 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- -1 sinapic acid choline ester Chemical class 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 23
- PCMORTLOPMLEFB-ONEGZZNKSA-N Sinapic acid Natural products COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 claims description 22
- 229960001231 choline Drugs 0.000 claims description 21
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 14
- 239000010685 fatty oil Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 12
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 12
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000013558 reference substance Substances 0.000 claims description 9
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000006463 Brassica alba Nutrition 0.000 abstract 1
- 244000140786 Brassica hirta Species 0.000 abstract 1
- 235000011371 Brassica hirta Nutrition 0.000 abstract 1
- 235000004347 Perilla Nutrition 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 104
- 208000006673 asthma Diseases 0.000 description 96
- 239000000243 solution Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 239000000843 powder Substances 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 241000700199 Cavia porcellus Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000000954 anitussive effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000000247 postprecipitation Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- NUXXPTJGCLKPIG-VDHCZMMKSA-N 2-[(e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]oxyethyl-trimethylazanium;[[2-(4-hydroxyphenyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylethylidene]amino] sulfate Chemical compound COC1=CC(C=CC(=O)OCC[N+](C)(C)C)=CC(OC)=C1O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1SC(=NOS([O-])(=O)=O)CC1=CC=C(O)C=C1 NUXXPTJGCLKPIG-VDHCZMMKSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000026636 chronic pulmonary heart disease Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- CGFYHILWFSGVJS-UHFFFAOYSA-N silicic acid;trioxotungsten Chemical compound O[Si](O)(O)O.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 CGFYHILWFSGVJS-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 给药量(g生药/kg) | 动物数(只) | 引咳潜伏期(S)(X±SD) | 5min咳嗽次数(X±SD) | P值** |
三子咳喘胶囊 | 10.00 | 14 | 30.27±10.70 | 8.43±6.59 | <0.01 |
三子咳喘胶囊 | 5.00 | 14 | 25.36±6.68 | 10.57±7.90 | <0.01 |
三子咳喘胶囊 | 2.50 | 14 | 23.86±6.13 | 12.79±5.27 | <0.05 |
桂龙咳喘宁胶囊 | 500mg* | 14 | 26.08±6.42 | 10.07±5.26 | <0.01 |
空白对照组 | --- | 14 | 19.00±4.50 | 20.29±8.58 |
组别 | 给药量(g生药/kg) | 动物数(只) | 引咳潜伏期(S)(X±SD) | 5min咳嗽次数(X±SD) | P值** |
三子咳喘胶囊 | 4.00 | 10 | 92.5±18.09 | 6.6±3.04 | <0.01 |
三子咳喘胶囊 | 2.00 | 10 | 70.5±16.70 | 7.9±3.86 | <0.05 |
三子咳喘胶囊 | 1.00 | 10 | 63.9±17.01 | 8.2±3.89 | <0.05 |
桂龙咳喘宁胶囊 | 500mg* | 10 | 78.1±19.87 | 6.7±4.12 | <0.01 |
空白对照组 | --- | 10 | 53.8±15.90 | 12.3±3.13 |
组别 | 给药量(g生药/kg) | 动物数(只) | 酚红量(ug/ml)(X±SD) | P值** |
三子咳喘胶囊 | 10.00 | 15 | 8.43±1.47 | <0.01 |
三子咳喘胶囊 | 5.00 | 15 | 6.77±1.37 | <0.05 |
三子咳喘胶囊 | 2.50 | 15 | 6.37±1.20 | <0.05 |
桂龙咳喘宁胶囊 | 500mg* | 15 | 7.65±1.20 | <0.01 |
空白对照组 | --- | 15 | 5.45±0.84 |
组别 | 给药量(g生药/kg) | 动物数(只) | 充痰毛细管长度(X±SDcm) | P值** |
三子咳喘胶囊 | 6.00 | 10 | 3.40±0.87 | <0.01 |
三子咳喘胶囊 | 3.00 | 10 | 2.91±0.61 | <0.05 |
三子咳喘胶囊 | 1.50 | 10 | 2.29±0.70 | >0.05 |
桂龙咳喘宁胶囊 | 500mg* | 10 | 3.27±0.70 | <0.01 |
空白对照组 | --- | 10 | 2.19±0.87 |
组别 | 给药量(g生药/kg) | 动物数 | 引喘潜伏期(X±SD) | P值*** | |
(只) | 给药前 | 给药后 | |||
三子咳喘胶囊 | 4.00 | 10 | 59.10±14.28 | 169.20±19.58 | <0.01 |
三子咳喘胶囊 | 2.00 | 10 | 60.70±14.45 | 81.20±20.03 | <0.05 |
三子咳喘胶囊 | 1.00 | 10 | 58.20±14.04 | 71.80±13.62 | >0.05 |
桂龙咳喘宁胶囊 | 500mg* | 10 | 62.40±21.56 | 122.10±30.95 | <0.01 |
空白对照组 | - | 10 | 61.90±21.31 | 66.30±14.21 |
组别 | 浴槽药浓度(g生药/ml) | n数 | 毛细管容积量(mm) | 拮抗百分率(%) | |
给His | 给药 | ||||
三子咳喘胶囊 | 1×10-2 | 8 | 17.5±3.0 | 5.4±1.3 | 69.14 |
三子咳喘胶囊 | 5×10-3 | 8 | 19.0±2.2 | 9.5±1.3 | 50.00 |
桂龙咳喘宁胶囊 | 5×10-4* | 8 | 19.1±2.1 | 6.5±1.1 | 65.97 |
组别 | 浴槽药浓度(g生药/ml) | n数 | 毛细管容积量(mm) | 拮抗百分率(%) | |
给Ach | 给药 | ||||
三子咳喘胶囊 | 1×10-2 | 8 | 18.5±2.1 | 7.6±1.3 | 58.92 |
三子咳喘胶囊 | 5×10-3 | 8 | 19.5±2.2 | 12.0±1.7 | 38.46 |
桂龙咳喘宁胶囊 | 5×10-4* | 8 | 19.8±2.6 | 10.9±1.8 | 45.00 |
组别 | 浴槽药浓度(g生药/ml) | n数 | 毛细管容积量(mm) | 拮抗百分率(%) | |
给5-HT | 给药 | ||||
三子咳喘胶囊 | 1×10-2 | 8 | 20.1±3.1 | 6.6±1.2 | 67.16 |
三子咳喘胶囊 | 5×10-3 | 8 | 18.9±2.1 | 13.3±2.1 | 29.63 |
桂龙咳喘宁胶囊 | 5×1-6* | 8 | 19.1±2.2 | 10.1±2.7 | 47.12 |
组别 | 给药量(g生药/kg) | 动物数(只) | 廓清指数K(X±SD) | P值** |
三子咳喘胶囊 | 10.00 | 10 | 0.0316±0.0057 | <0.05 |
三子咳喘胶囊 | 5.00 | 10 | 0.0299±0.0040 | <0.05 |
三子咳喘胶囊 | 2.50 | 10 | 0.0264±0.0033 | >0.05 |
桂龙咳喘宁胶囊 | 500mg* | 10 | 0.0316±0.0050 | <0.05 |
空白对照组 | 10 | 0.0254±0.0048 |
组别 | 给药量(g生药/kg) | 动物数(只) | 游泳持续时间min(X±SD) | P值 |
三子咳喘胶囊 | 10.00 | 10 | 48.40±12.40 | <0.05 |
三子咳喘胶囊 | 5.00 | 10 | 40.62±12.62 | >0.05 |
桂龙咳喘宁胶囊 | 500mg* | 10 | 54.39±11.79 | <0.01 |
空白对照组 | --- | 10 | 38.07±9.36 |
药物浓度 | 0.1000 | 0.0500 | 0.0250 | 0.0125 | 0.0063 | 0.0031 | 0.0016 | 青霉素 | 链霉素 |
菌株金葡菌链球菌肺炎球菌沙门氏菌志贺氏菌大肠杆菌绿脓杆菌 | 13.4811.2012.359.858.2810.4012.68 | 11.758.4510.867.605.768.659.75 | 9.565.887.644.383.555.906.40 | 6.804.054.952.561.883.574.18 | 4.302.763.051.200.1.852.32 | 1.751.101.500.0.0.1.05 | 00000.0.0. | 25.3821.4526.758.20--------- | 12.8510.2011.4615.8512.4013.78--- |
药物浓度 | 0.5000 | 0.2500 | 0.1250 | 0.0625 | 0.0313 | 0.0156 | 0.0078 | 0.0039 | 0.0020 | 0.001 |
菌株金葡菌链球菌肺炎球菌沙门杆菌志贺氏菌大肠杆菌绿脓杆菌 | --------------------- | --------------------- | --------------------- | --------------------- | --------------------- | --------------------- | ------------+++ | ++++++++++ | +++++++++++++++ | +++++++++++++++++++++ |
菌株 | 纸片法 | 试管法 |
金葡菌链球菌肺炎球菌沙门杆菌志贺氏菌大肠杆菌绿脓杆菌 | 0.00310.00310.00310.00630.01250.00630.0031 | 0.00780.00780.00780.00780.01560.01560.0156 |
组别 | 给药量(g生药/kg) | 耳片数(只) | 耳片重mg(X±SD) | P值** |
三子咳喘胶囊 | 10.0 | 20 | 24.72±5.49 | P<0.05 |
三子咳喘胶囊 | 5.0 | 20 | 27.43±2.53 | P>0.05 |
桂龙咳喘宁胶囊 | 500mg* | 20 | 24.51±4.21 | P<0.05 |
空白对照组 | --- | 20 | 28.75±5.30 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101001643A CN1313109C (zh) | 2003-10-14 | 2003-10-14 | 三子汤新制剂及其制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101001643A CN1313109C (zh) | 2003-10-14 | 2003-10-14 | 三子汤新制剂及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1528391A CN1528391A (zh) | 2004-09-15 |
CN1313109C true CN1313109C (zh) | 2007-05-02 |
Family
ID=34303988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101001643A Expired - Lifetime CN1313109C (zh) | 2003-10-14 | 2003-10-14 | 三子汤新制剂及其制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1313109C (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100406056C (zh) * | 2005-06-03 | 2008-07-30 | 龚泉福 | 一种营养口服液 |
SG177414A1 (en) * | 2009-06-30 | 2012-02-28 | Hebei Yiling Medicine Res Inst Co Ltd | Pharmaceutical composition containing ephedrae herba for treating bronchitis and preparation method thereof |
MY172035A (en) * | 2009-06-30 | 2019-11-12 | Hebei Yiling Medicine Res Institute Co Ltd | A medicinal composition for the treatment of bronchitis and preparation thereof |
CN104940487A (zh) * | 2015-06-05 | 2015-09-30 | 吴斌 | 一种用于治疗支气管哮喘的药物 |
CN107233516A (zh) * | 2017-08-11 | 2017-10-10 | 王美美 | 一种治疗哮喘的中药配方及制备方法 |
CN107582626A (zh) * | 2017-10-17 | 2018-01-16 | 朱晓军 | 消咳喘痰湿散制备方法 |
KR20190109220A (ko) | 2018-03-16 | 2019-09-25 | 주식회사 헬릭스미스 | 호흡기 질환의 예방 또는 치료용 생약 조성물 |
CN110441432A (zh) * | 2019-08-23 | 2019-11-12 | 广东一方制药有限公司 | 一种芥子及其炮制品特征图谱的构建方法 |
CN112138082A (zh) * | 2020-10-26 | 2020-12-29 | 郑州金鸽生物技术开发有限公司 | 一种治疗肺病的组合物及其制备方法 |
-
2003
- 2003-10-14 CN CNB2003101001643A patent/CN1313109C/zh not_active Expired - Lifetime
Non-Patent Citations (3)
Title |
---|
三子养亲汤的研究进展 潘洪平等,中成药,第18卷第12期 1996 * |
大孔吸附树脂对白芥子生物碱提取分离的应用研究 谢朝晖等,湖南中医杂志,第18卷第3期 2002 * |
大孔吸附树脂对白芥子生物碱提取分离的应用研究 谢朝晖等,湖南中医杂志,第18卷第3期 2002;三子养亲汤的研究进展 潘洪平等,中成药,第18卷第12期 1996 * |
Also Published As
Publication number | Publication date |
---|---|
CN1528391A (zh) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1401334A (zh) | 复方双黄连制剂及制备方法 | |
CN1876139A (zh) | 治疗小儿厌食症的药物制剂及其制备方法和质量控制方法 | |
CN101040915A (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN1313109C (zh) | 三子汤新制剂及其制备 | |
CN1723955A (zh) | 射干提取物及其制备方法和用途 | |
CN1405314A (zh) | 隐孔菌发酵产物及其制备方法和应用 | |
CN1872199A (zh) | 一种中药组合物及其制备方法 | |
CN1186051C (zh) | 一种化痰止咳的药物及其生产方法 | |
CN1118471C (zh) | 鞣料云实素的制备工艺 | |
CN1517124A (zh) | 具有解热作用的中药组合物及其制备方法和质量控制方法 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN100339101C (zh) | 藿香正气滴丸的制备方法及其用途 | |
CN101077341A (zh) | 橙黄决明素或其衍生物在制备降血脂药物中的应用 | |
CN111643582B (zh) | 一种泽泻叶提取物及其制备方法 | |
CN1291734C (zh) | 一种中药软胶囊制剂的质量控制方法 | |
CN1857424A (zh) | 一种中药复方制剂及其制备方法、质量控制方法 | |
CN1272290C (zh) | 栀子环烯醚萜总提物及其制备方法和用途 | |
CN100337658C (zh) | 治疗感冒风热症的中药组合物及其制备方法 | |
CN101032571A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1506092A (zh) | 一种治疗腹泻的香薷提取物胶囊制剂及其制备方法 | |
CN1903343A (zh) | 一种治疗胆道结石的药物组合物及其制备方法和用途 | |
CN1566136A (zh) | 白头翁总皂苷及提取方法,以及医药用途和药物制剂 | |
CN1919270A (zh) | 组合物,其提取物及它们的药物用途 | |
CN1839863A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN1850132A (zh) | 一种百蕊颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070502 |